Jasper Therapeutics

About Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutic agents for hematopoietic stem cell transplantation, gene therapies, and mast cell-driven diseases. The company’s lead product candidate, briquilimab, is a targeted anti-KIT monoclonal antibody designed to deplete mast cells and clear hematopoietic stem cells from bone marrow, enabling safer and more effective conditioning regimens for stem cell therapy and gene therapy. Jasper Therapeutics is advancing clinical studies in chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma, and is developing therapies for rare diseases such as sickle cell disease, Fanconi anemia, chronic granulomatous disease, GATA2 MDS, and severe combined immunodeficiency. The company is headquartered in Redwood City, California, and serves customers worldwide.